A selective dopamine D3 antagonist
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

SB 277011A (hydrochloride)

Item No. 11982

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
N-[trans-4-[2-(6-cyano-3,4-dihydro-2(1H)-isoquinolinyl)ethyl]cyclohexyl]-4-quinolinecarboxamide, dihydrochloride
CAS Number
1226917-67-4
Molecular Formula
C28H30N4O • 2HCl
Formula Weight
511.5
Purity
≥98%
Formulation
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 3 mg/mlDMSO: 14 mg/mlDMSO:PBS (pH 7.2)(1:9): 0.1 mg/mlEthanol: 0.1 mg/ml
λmax
230, 284 nm
SMILES
O=C(C1=C2C(C=CC=C2)=NC=C1)N[C@H](CC3)CC[C@@H]3CCN(C4)CCC5=C4C=CC(C#N)=C5.Cl.Cl
InChi Code
InChI=1S/C28H30N4O.2ClH/c29-18-21-5-8-23-19-32(16-13-22(23)17-21)15-12-20-6-9-24(10-7-20)31-28(33)26-11-14-30-27-4-2-1-3-25(26)27;;/h1-5,8,11,14,17,20,24H,6-7,9-10,12-13,15-16,19H2,(H,31,33);2*1H/t20-,24-;;
InChi Key
HEZIOTGUXSPDAK-ONAIBGCWSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $49

    Add

    5 mg

    $130

    Add

    10 mg

    $213

    Add

    25 mg

    $469

    Add
    Product Description

    SB 277011A is an antagonist of the dopamine D3 receptor (pKi = 8.0) that is at least 100-fold selective for D3 over other monoamine receptors (pKis = 6.0, 5.0, and <5.2 for D2, 5-HT1D and 5-HT1B respectively).1,2,3 It has high oral bioavailability and enters the central nervous system of the rat.1 SB 277011A has been shown to have potential benefits in animal models of schizophrenia and Parkinson’s disease.2,4

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Stemp, G., Ashmeade, T., Branch, C.L., et al. Design and synthesis of trans-N-[4-[2-(6-cyano-1,2,3, 4-tetrahydroisoquinolin-2-yl)ethyl]cyclohexyl]-4-quinolinecarboxamide (SB-277011): A potent and selective dopamine D(3) receptor antagonist with high oral bioavailability and CNS penetration in the rat. J. Med. Chem. 43(9), 1878-1885 (2000).

    2. Reavill, C., Taylor, S.G., Wood, M.D., et al. Pharmacological actions of a novel, high-affinity, and selective human dopamine D(3) receptor antagonist, SB-277011-A. J. Pharmacol. Exp. Ther. 294(3), 1154-1165 (2000).

    3. Heidbreder, C.A., Gardner, E.L., Xi, Z.-X., et al. The role of central dopamine D3 receptors in drug addiction: a review of pharmacological evidence. Brain Res.Rev. 49(1), 77-105 (2005).

    4. Carcinella, S., Drui, G., Boulet, S., et al. Implication of dopamine D3 receptor activation in the reversion of Parkinson’s disease-related motivational deficits. Transl. Psychiatry 4(6), e401 (2014).